HK1208475A1 - 防止生物膜形成的方法 - Google Patents

防止生物膜形成的方法

Info

Publication number
HK1208475A1
HK1208475A1 HK15109048.6A HK15109048A HK1208475A1 HK 1208475 A1 HK1208475 A1 HK 1208475A1 HK 15109048 A HK15109048 A HK 15109048A HK 1208475 A1 HK1208475 A1 HK 1208475A1
Authority
HK
Hong Kong
Prior art keywords
methods
biofilm formation
preventing biofilm
preventing
formation
Prior art date
Application number
HK15109048.6A
Other languages
English (en)
Inventor
Jeremy Yethon
Astrid Rey
Sylvie Lefort
Laurent Fraisse
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1208475A1 publication Critical patent/HK1208475A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15109048.6A 2012-05-07 2015-09-16 防止生物膜形成的方法 HK1208475A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261643650P 2012-05-07 2012-05-07
PCT/US2013/039724 WO2013169657A1 (en) 2012-05-07 2013-05-06 Methods for preventing biofilm formation

Publications (1)

Publication Number Publication Date
HK1208475A1 true HK1208475A1 (zh) 2016-03-04

Family

ID=48464117

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109048.6A HK1208475A1 (zh) 2012-05-07 2015-09-16 防止生物膜形成的方法

Country Status (8)

Country Link
EP (1) EP2847216A1 (zh)
CN (1) CN104662042A (zh)
AU (1) AU2013259786A1 (zh)
CA (1) CA2872856A1 (zh)
HK (1) HK1208475A1 (zh)
MX (1) MX2014013637A (zh)
SG (1) SG11201407209YA (zh)
WO (1) WO2013169657A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220107001A (ko) * 2019-11-22 2022-08-01 알로펙스, 인크. Pnag 포함 미생물에 대한 연속 치료를 제공하는 방법

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ES2300113T3 (es) 1996-08-02 2008-06-01 Bristol-Myers Squibb Company Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7425619B2 (en) 2002-08-14 2008-09-16 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION

Also Published As

Publication number Publication date
MX2014013637A (es) 2015-02-05
WO2013169657A1 (en) 2013-11-14
EP2847216A1 (en) 2015-03-18
CN104662042A (zh) 2015-05-27
CA2872856A1 (en) 2013-11-14
AU2013259786A1 (en) 2014-11-20
SG11201407209YA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
HK1250690A1 (zh) 方法
HK1203196A1 (zh) 取代的苄基吡唑
HK1208363A1 (zh) 新方法
HK1248702A1 (zh) 取代的吡咯烷-2-甲酰胺
HK1200830A1 (zh) 取代的吡咯烷- -甲酰胺
HK1206724A1 (zh) 取代的苯並噻吩並嘧啶
HK1209422A1 (zh) 抑制劑
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
GB2507760B (en) Methods
HK1206022A1 (zh) 取代的咪唑並噠嗪
EP2880048A4 (en) METHOD
GB201208874D0 (en) Methods
GB201202198D0 (en) Method
GB201204280D0 (en) Methods
HK1208475A1 (zh) 防止生物膜形成的方法
HK1212895A1 (zh) 用於免疫調節的沙奎那韋-
GB201208756D0 (en) Methods
GB201203337D0 (en) Method
GB201201332D0 (en) Method
EP2639418A4 (en) EXHAUST HEATING METHOD
GB201220686D0 (en) Methods
AP2012000550S (en) E-horn methods
GB201216074D0 (en) Methods
GB201209689D0 (en) Methods
GB201208875D0 (en) Methods